Stocks poised to move as this corner of the cancer therapy market heats up
Radiopharmaceuticals seek to destroy cancer cells by binding a radioactive particle to a targeted molecule and then dispatching it directly into the tumor.
Stay updated with breaking news from Perspective Therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Radiopharmaceuticals seek to destroy cancer cells by binding a radioactive particle to a targeted molecule and then dispatching it directly into the tumor.
Perspective Therapeutics, Inc. (NYSE:CATX – Get Free Report) has been given a consensus rating of “Buy” by the six ratings firms that are covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 1 year price target among brokerages that have issued ratings on the stock in […]
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) shares saw an uptick in trading volume on Thursday . 6,515,337 shares were traded during trading, an increase of 56% from the previous session’s volume of 4,163,777 shares.The stock last traded at 1.59 and had previously closed at 1.57. Wall Street Analysts Forecast Growth Several research firms […]
SEATTLE, May 03, 2024 -- Perspective Therapeutics, Inc. , a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that...
Lantheus Holdings, Inc. beats earnings expectations. Reported EPS is $1.69, expectations were $1.55. Lantheus Holdings, Inc.